Patents by Inventor Jim Turpin

Jim Turpin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents
    Patent number: 8076372
    Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: December 13, 2011
    Assignee: Government of the United States
    Inventors: John K. Inman, Atul Goel, Ettore Appella, Jim A. Turpin, Marco Schito
  • ACYTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS
    Publication number: 20090247473
    Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.
    Type: Application
    Filed: March 30, 2009
    Publication date: October 1, 2009
    Applicant: THE GOVERNMENT OF THE U.S.A.,as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: John K. Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
  • Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents
    Patent number: 7528274
    Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: May 5, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: John K. Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
  • Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents
    Publication number: 20050020831
    Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.
    Type: Application
    Filed: July 25, 2002
    Publication date: January 27, 2005
    Inventors: John Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
  • Method for obtaining soluble antitumor factor
    Patent number: 5213970
    Abstract: Disclosed herein is a novel antitumor factor, termed Human Monocyte Toxin, obtained by the precise activation of cells of monocyte/macrophage lineage. Monocytes are isolated in the absence of endotoxin by counterflow elutriation. HMT release can be triggered by exposure to low levels of 6-0-stearoyl muramyl dipeptide, lipopolysaccharide, phorbol myristate acetate or other known macrophage activating agents. Triggering results in the rapid release of HMT which requires transcription, translation, and intact secretory apparatus. The requirement for precise control of the triggering agent concentration is disclosed.The government may have certain rights in the present invention pursuant to NIH grant BRSG 5511.
    Type: Grant
    Filed: January 23, 1987
    Date of Patent: May 25, 1993
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gabriel Lopez-Berestein, Jim Klostergaard, Jim Turpin